Pharmacokinetic Study on Raltegravir and Lamotrigine

Radboud University Medical Center24 enrolled

Overview

The purpose of this study is to determine whether interactions between raltegravir and lamotrigine take place and to study the safety of the combination raltegravir/lamotrigine before used in HIV patients.

Lamotrigine is an anticonvulsive drug that is used both for the treatment of HIV-associated neuropathic pain and the treatment of epilepsy in HIV-infected individuals. Lamotrigine is metabolized via glucuronidation. Raltegravir is a newly developed integrase inhibitor that is also metabolized via glucuronidation. Since both agents are metabolized via glucuronidation, there is a possibility of competition for glucuronidation, leading to drug-drug interactions between raltegravir and lamotrigine. This primary objective of this study is to determine the effect of raltegravir on the pharmacokinetics of single dose lamotrigine (by intrasubject comparison). A secondary objective is to determine the effect of single dose lamotrigine on the pharmacokinetics of raltegravir when compared to historical controls. Another secondary objective is to evaluate the safety of combined use of single dose lamotrigine and raltegravir.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

HIV Infection

Interventions

lamotrigineDRUG

100 mg

RaltegravirDRUG

400 mg BD

Eligibility

Sex: MALEMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Between 18 and 55 years of age * Subject does not smoke more than 10 cigarettes, 2 cigars or 2 pipes per day * Subject has a Quetelet Index of 18 to 30 kg/m2 * Subject is able and willing to sign informed consent * Subject is in good age-appropriate health condition * Subject has a normal blood pressure and pulse rate Exclusion Criteria: * History of sensitivity/idiosyncrasy to medicinal products or excipients * Positive HIV test * Positive hepatitis B or C test * Therapy with any drug (2 weeks preceding dosing) except for paracetamol * Relevant history or presence of pulmonary disorders, cardiovascular * History of or current abuse of drugs, alcohol or solvents * Inability to understand the nature and extent of the trial and procedures * Participation in a drug trial within 60 days prior to the first dose * Donation of blood within 60 days prior to the first dose * Febrile illness within 3 days before the first dose

Locations (1)

Radboud University Medical Center

Nijmegen, Gelderland, Netherlands

Outcomes

Primary Outcomes

Plasma concentrations of lamotrigine, lamotrigine-2N-glucuronide, and raltregravir

Time frame: just before dosing, at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 24 hours and 48 hours after dosing on study days 4-5 and 32-33.

Secondary Outcomes

Determination of pharmacokinetic parameters (AUC, Cmax, Tmax, Cmin and T 1/2) by noncompartmental analysis

Time frame: at each sampling time

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.